journal article·2025-06-18

pH-Responsive Diblock Copolymer Vesicles via Polymerization-Induced Self-Assembly in Aqueous Media: Synthesis, Loading, and Potential Biological Applications

Jake G. Edmans, Asma El-Howati, Klaudia M. Slowik, Helen E. Colley, Craig Murdoch, Paul V. Hatton, Steven P. Armes

ACS Applied Materials & Interfaces· Volume 17· Issue 24
Publisher page

Abstract

Polymerization-induced self-assembly (PISA) offers a useful strategy for the efficient encapsulation of biomacromolecules within diblock copolymer vesicles under mild conditions. This approach eliminates the need for a separate vesicle loading step and should be particularly advantageous for drug delivery applications if suitable biocompatible vesicles can be designed to release their encapsulated cargo in response to a specific environmental stimulus. Ideally, the vesicles should remain intact after endocytosis but subsequently undergo dissociation when exposed to the mildly acidic conditions (pH ∼5) found within intracellular endosomal compartments of mammalian cells. In this study, reversible addition–fragmentation chain-transfer (RAFT) aqueous dispersion copolymerization of 2-hydroxypropyl methacrylate (HPMA) with 2- N -(morpholino)ethyl methacrylate (MEMA) was conducted using a water-soluble poly(glycerol monomethacrylate) (PGMA) precursor to prepare a series of PGMA-P(HPMA- stat -MEMA) copolymer vesicles. Such vesicles exhibit tunable pH-responsive behavior, leading to their dissociation between pH 3.5 and 6 depending on their MEMA content. F(ab) antibody fragments were loaded within these vesicles during their aqueous PISA synthesis at 45 °C with an encapsulation efficiency of 42 ± 4%: this antibody retains its antigen-binding functionality and is subsequently released from the vesicles at pH ≤5.25. Furthermore, nanoflow cytometry analysis confirms the encapsulation of plasmid DNA within these vesicles and their subsequent take-up by human keratinocytes highlights the versatility of this technique for biotherapeutic delivery. This is the first reported example of PISA being used to prepare vesicles loaded with either antibody fragments or nucleic acids that can be subsequently released under physiologically relevant conditions, without requiring additional reactions or postpolymerization loading steps. In principle, encapsulation of proteins, antibodies, enzymes, or oligonucleotides within vesicles during their PISA synthesis has the potential to significantly advance nanomedicine.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Polymer Synthesis and Characterization · Polymer Surface Interaction Studies · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Dainton Building, School of Mathematical and Physical Sciences, University of Sheffield, Brook Hill, Sheffield, South Yorkshire S3 7HF, U.K.

School of Clinical Dentistry, University of Sheffield, 19 Claremont Crescent, Sheffield, South Yorkshire S10 2TA, U.K.

Insigneo Institute, Sheffield, U.K., The Pam Liversidge Building, Sheffield S1 3JD U.K.

Funding

Engineering and Physical Sciences Research Council · Biotechnology and Biological Sciences Research Council

References (70)

Show source-provided references
1. 10.1002/marc.20080071310.1002/marc.200800713 ↗
2. 10.1039/b905635a10.1039/b905635a ↗
3. 10.1126/science.284.5417.114310.1126/science.284.5417.1143 ↗
4. 10.1002/anie.20070112510.1002/anie.200701125 ↗
5. 10.1021/acsami.3c1062010.1021/acsami.3c10620 ↗
6. 10.1021/acs.biomac.6b0170410.1021/acs.biomac.6b01704 ↗
7. 10.1021/ja056514l10.1021/ja056514l ↗
8. 10.1002/adma.20070094110.1002/adma.200700941 ↗
9. 10.3390/ma1702031910.3390/ma17020319 ↗
10. 10.1016/j.jconrel.2003.12.02110.1016/j.jconrel.2003.12.021 ↗
11. 10.1039/c1py00061f10.1039/c1py00061f ↗
12. 10.1021/acs.biomac.9b0175410.1021/acs.biomac.9b01754 ↗
13. 10.1039/C9MH01669D10.1039/C9MH01669D ↗
14. 10.1021/mp400610b10.1021/mp400610b ↗
15. 10.1021/acs.biomac.0c0082410.1021/acs.biomac.0c00824 ↗
16. 10.1039/D0PY01247E10.1039/D0PY01247E ↗
17. 10.2147/IJN.S44491010.2147/IJN.S444910 ↗
18. 10.1016/j.jconrel.2007.04.00410.1016/j.jconrel.2007.04.004 ↗
19. 10.1021/nn102762f10.1021/nn102762f ↗
20. 10.1002/anie.20080589510.1002/anie.200805895 ↗
21. 10.1016/j.isci.2018.08.01810.1016/j.isci.2018.08.018 ↗
22. Chierico, L. Polymersomes Mediated Intracellular Delivery of Antibodies: Implication in Anticancer Therapy; PhD Thesis; University College London, 2015.
23. 10.1096/fj.12-21218310.1096/fj.12-212183 ↗
24. 10.1002/ange.20120416910.1002/ange.201204169 ↗
25. Patikarnmonthon, N. Optimisation of Polymersomes Preparation and SiRNA Encapsulation; PhD Thesis; University of Sheffield, 2013.
26. 10.1021/acs.macromol.5b0260210.1021/acs.macromol.5b02602 ↗
27. 10.1002/anie.20191175810.1002/anie.201911758 ↗
28. 10.1021/ja502843f10.1021/ja502843f ↗
29. 10.1021/ma301059r10.1021/ma301059r ↗
30. 10.1016/j.jcis.2022.03.04410.1016/j.jcis.2022.03.044 ↗
31. 10.1002/adma.20240800010.1002/adma.202408000 ↗
32. 10.1016/j.bioadv.2023.21373410.1016/j.bioadv.2023.213734 ↗
33. 10.1039/D0BM01406K10.1039/D0BM01406K ↗
34. 10.1021/jacs.5b1041510.1021/jacs.5b10415 ↗
35. 10.1021/acsmacrolett.5b0074810.1021/acsmacrolett.5b00748 ↗
36. 10.1021/acsmacrolett.7b0072510.1021/acsmacrolett.7b00725 ↗
37. 10.1039/D2SC02103J10.1039/D2SC02103J ↗
38. 10.1021/acsomega.2c0403610.1021/acsomega.2c04036 ↗
39. 10.1021/acsmacrolett.0c0015110.1021/acsmacrolett.0c00151 ↗
40. 10.1021/acscentsci.8b0016810.1021/acscentsci.8b00168 ↗
41. 10.1016/j.tips.2021.03.00210.1016/j.tips.2021.03.002 ↗
42. 10.1038/nmeth.208910.1038/nmeth.2089 ↗
43. 10.1016/j.jconrel.2022.08.01610.1016/j.jconrel.2022.08.016 ↗
44. 10.1021/acs.jpcb.5b0289110.1021/acs.jpcb.5b02891 ↗
45. 10.1089/ten.tec.2016.031010.1089/ten.tec.2016.0310 ↗
46. 10.1021/ja206301a10.1021/ja206301a ↗
47. 10.1007/s12551-016-0218-610.1007/s12551-016-0218-6 ↗
48. 10.1039/D1PY01020D10.1039/D1PY01020D ↗
49. 10.1016/S0032-3861(01)00066-010.1016/S0032-3861(01)00066-0 ↗
50. 10.1021/ma011541r10.1021/ma011541r ↗
51. 10.1039/C4PY00203B10.1039/C4PY00203B ↗
52. 10.1002/marc.20160052810.1002/marc.201600528 ↗
53. 10.1021/acs.macromol.9b0014410.1021/acs.macromol.9b00144 ↗
54. 10.1039/D1RA05555K10.1039/D1RA05555K ↗
55. 10.1021/acs.macromol.4c0042710.1021/acs.macromol.4c00427 ↗
56. 10.1002/marc.20200026010.1002/marc.202000260 ↗
57. 10.1002/anie.20140979910.1002/anie.201409799 ↗
58. 10.1039/C5PY01510C10.1039/C5PY01510C ↗
59. 10.1039/D1SC05022B10.1039/D1SC05022B ↗
60. 10.1039/D1PY01114F10.1039/D1PY01114F ↗
61. 10.1039/C7SC04788F10.1039/C7SC04788F ↗
62. 10.1039/C8SC05589K10.1039/C8SC05589K ↗
63. 10.1021/acs.macromol.3c0044510.1021/acs.macromol.3c00445 ↗
64. 10.1021/acs.macromol.8b0208110.1021/acs.macromol.8b02081 ↗
65. 10.1016/j.biotechadv.2013.11.00910.1016/j.biotechadv.2013.11.009 ↗
66. 10.1039/c2cs15309b10.1039/c2cs15309b ↗
67. 10.1016/j.ejpb.2018.05.03410.1016/j.ejpb.2018.05.034 ↗
68. 10.1002/marc.20160050810.1002/marc.201600508 ↗
69. 10.1021/acs.macromol.2c0195310.1021/acs.macromol.2c01953 ↗
70. 10.1038/nrd.2017.22710.1038/nrd.2017.227 ↗